Come up with a name for your new list and we'll add to it:
Medicenna Therapeutics raised a round of funding on February 23, 2015. Investors include
Cancer Prevention and Research Institute of Texas.
Medicenna is a clinical stage, privately held, immuno-oncology company developing first-in-class, Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R)…